Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
2019
Background
With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in clinical settings. The underlying molecular mechanism and safety of stem cell treatment in POI are not fully understood. In this study, we explored whether fetal mesenchymal stem cells (fMSCs) from the liver restore ovarian function and whether melatonin membrane receptor 1 (MT1) acts as a regulator for treating POI disease.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
59
References
13
Citations
NaN
KQI